Fri, Jul 25, 2014, 12:01 AM EDT - U.S. Markets open in 9 hrs 29 mins

Recent

% | $
Click the to save as a favorite.

Endocyte, Inc. (ECYT) Message Board

  • nferna@parknet.pmh.org nferna Feb 21, 2014 9:39 AM Flag

    Yondelis

     

    The EMA website is fantastic and getting better each month with the information they are providing. Huge resource for us little guys.

    Case in point:

    If you look up the page for Yondelis, a drug approved for treatment of platinum sensitive ovarian cancer, you will find the following in the FAQ:

    "What benefit has Yondelis shown during the studies?

    For ovarian cancer, the combination of Yondelis and PLD was more effective than PLD alone: patients receiving the combination treatment lived for an average of 7.3 months without their disease getting worse, compared with 5.8 months in those receiving PLD alone. The effect of Yondelis was more pronounced in the women whose cancer was sensitive to platinum-containing medicines."

    This is from the EMA's own website!

    In PROC FR100 patients, vintafolide plus PLD yielded 5.5 month PFS vs 1.5 months for PLD alone (PRECEDENT data)

    Now, this is not an apples-to-apples comparison, because this was a second indication for Yondelis.

    You be the judge. I am not selling my shares until we see this through. This month, next month, whatever.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ECYT
6.31+0.07(+1.12%)Jul 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.